“An oral GLP-1 receptor agonist combined with an ERRα/γ agonist for comprehensive metabolic optimization.”

Orforglipron is a small molecule that directly binds to and activates the GLP-1 receptor (GLP1R), a G-protein coupled receptor expressed in the pancreas, brain, gut, and other tissues. GLP-1 receptor activation in the pancreas enhances glucose-stimulated insulin secretion; in the brain (hypothalamus and brainstem), it reduces appetite and food intake through multiple neuropeptide signaling pathways; in the gut, it slows gastric emptying to reduce post-meal glucose spikes. As a non-peptide small molecule, Orforglipron has high oral bioavailability unlike peptide GLP-1 agonists (semaglutide, liraglutide) that require injection. SLU-PP-332 activates ERRalpha and ERRgamma nuclear receptors, transcription factors that regulate hundreds of genes involved in mitochondrial biogenesis, oxidative phosphorylation, and fatty acid oxidation — essentially programming cells to burn more fat and produce more mitochondria, mimicking the molecular adaptations of endurance exercise.